Surrogate endpoints for clinical trials in primary sclero: results from an International PSC Study Group consens

Hepatology

63, 1357-1367

DOI: 10.1002/hep.28256

Citation Report

#	Article	IF	Citations
1	Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value. Liver International, 2016, 36, 1867-1875.	1.9	70
2	Novel Aspects in the Management of Cholestatic Liver Diseases. Digestive Diseases, 2016, 34, 340-346.	0.8	15
3	Primary Sclerosing Cholangitis. New England Journal of Medicine, 2016, 375, 1161-1170.	13.9	358
4	Prognostic biomarkers and surrogate end points in <scp>PSC</scp>. Liver International, 2016, 36, 1748-1751.	1.9	1
5	Enhanced liver fibrosis test predicts transplantâ€free survival in primary sclerosing cholangitis, a multiâ€centre study. Liver International, 2017, 37, 1554-1561.	1.9	54
6	Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. Journal of Hepatology, 2017, 66, 1214-1222.	1.8	51
7	Emerging treatments for primary sclerosing cholangitis. Expert Review of Gastroenterology and Hepatology, 2017, 11, 451-459.	1.4	12
8	Emerging pharmacologic therapies for primary sclerosing cholangitis. Current Opinion in Gastroenterology, 2017, 33, 149-157.	1.0	14
9	Pharmacological interventions for primary sclerosing cholangitis. The Cochrane Library, 2017, 2017, CD011343.	1.5	21
10	Pathological Features of Biliary Disease in Children and Adults. , 2017, , 43-61.		0
11	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 549-558.	1.8	202
12	Genetics of primary sclerosing cholangitis and pathophysiological implications. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 279-295.	8.2	93
13	Prognostic scores and non-invasive markers in primary sclerosing cholangitis: good for patients or for papers?. The Lancet Gastroenterology and Hepatology, 2017, 2, 774-776.	3.7	3
14	Does transient elastography correlate with liver fibrosis in patients with PSC? Laennec score-based analysis of explanted livers. Scandinavian Journal of Gastroenterology, 2017, 52, 1407-1412.	0.6	14
15	Primary sclerosing cholangitis and the management of uncertainty and complexity. Frontline Gastroenterology, 2017, 8, 260-266.	0.9	10
16	Primary sclerosing cholangitis â€“ a comprehensive review. Journal of Hepatology, 2017, 67, 1298-1323.	1.8	538
17	Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol. BMJ Open, 2017, 7, e015081.	0.8	23
18	24-Norursodeoxycholic acid in patients with primary sclerosing cholangitis: A new â€œurso sagaâ€•on the horizon?. Journal of Hepatology, 2017, 67, 446-447.	1.8	5

#	Article	IF	Citations
19	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology, 2017, 65, 907-919.	3.6	79
20	Editorial: vancomycin â€“ a promising option for the treatment of primary sclerosing cholangitis?. Alimentary Pharmacology and Therapeutics, 2018, 47, 1321-1322.	1.9	3
22	Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. Hepatology, 2018, 68, 1174-1188.	3.6	42
23	MR elastography in primary sclerosing cholangitis: correlating liver stiffness with bile duct strictures and parenchymal changes. Abdominal Radiology, 2018, 43, 3260-3270.	1.0	22
24	Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2018, 47, 886-895.	1.9	57
25	Primary sclerosing cholangitis. Lancet, The, 2018, 391, 2547-2559.	6.3	276
26	Quality of life and primary sclerosing cholangitis: The business of defining what counts. Hepatology, 2018, 68, 16-18.	3.6	9
27	New therapies target the toxic consequences of cholestatic liver disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 277-285.	1.4	14
28	Hepatic Stem/Progenitor Cell Activation Differs between Primary Sclerosing and Primary Biliary Cholangitis. American Journal of Pathology, 2018, 188, 627-639.	1.9	59
29	Metal, magnet or transplant: options in primary sclerosing cholangitis with stricture. Hepatology International, 2018, 12, 510-519.	1.9	2
30	Clinical guidelines for primary sclerosing cholangitis 2017. Journal of Gastroenterology, 2018, 53, 1006-1034.	2.3	39
31	Emerging therapeutic targets for primary sclerosing cholangitis. Expert Opinion on Orphan Drugs, 2018, 6, 393-401.	0.5	0
32	Bile Duct Diseases. , 2018, , 515-593.		12
33	Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases. Orphanet Journal of Rare Diseases, 2018, 13, 104.	1.2	16
34	Support of precision medicine through risk-stratification in autoimmune liver diseases â€“ histology, scoring systems, and non-invasive markers. Autoimmunity Reviews, 2018, 17, 854-865.	2.5	29
35	Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: Frenchâ€“Spanish experience. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 521-528.	0.7	40
37	The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. Liver International, 2018, 38, 2329-2339.	1.9	22
38	Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis. PLoS ONE, 2018, 13, e0193929.	1.1	8

#	Article	IF	Citations
39	An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 192-199.e3.	2.4	16
40	Prospective comparison of diffusion-weighted MRI and dynamic Gd-EOB-DTPA-enhanced MRI for detection and staging of hepatic fibrosis in primary sclerosing cholangitis. European Radiology, 2019, 29, 818-828.	2.3	9
41	Longâ€term outcomes of pediatricâ€onset primary sclerosing cholangitis: A singleâ€center experience in Japan. Hepatology Research, 2019, 49, 1386-1397.	1.8	4
42	Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. Journal of Hepatology, 2019, 71, 992-999.	1.8	25
43	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GSâ€9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 788-801.	3.6	180
44	Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. Scandinavian Journal of Gastroenterology, 2019, 54, 633-639.	0.6	23
45	British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut, 2019, 68, 1356-1378.	6.1	168
46	Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. Archivum Immunologiae Et Therapiae Experimentalis, 2019, 67, 197-211.	1.0	12
47	Precision medicine in primary sclerosing cholangitis. Journal of Digestive Diseases, 2019, 20, 346-356.	0.7	6
48	Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. Journal of Hepatology, 2019, 71, 603-615.	1.8	27
49	Magnetic Resonance Imaging in Primary Sclerosing Cholangitisâ€"Current State and Future Directions. Seminars in Liver Disease, 2019, 39, 369-380.	1.8	17
50	Emerging novel treatments for autoimmune liver diseases. Hepatology Research, 2019, 49, 489-499.	1.8	15
51	Rate of Spleen Length Progression Is a Marker of Outcome in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2613-2615.	2.4	8
52	Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. American Journal of Gastroenterology, 2019, 114, 1071-1079.	0.2	155
53	UEG Week 2019 Poster Presentations. United European Gastroenterology Journal, 2019, 7, 189-1030.	1.6	6
54	Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology, 2019, 69, 684-698.	3.6	121
55	Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. Journal of Hepatology, 2019, 70, 483-493.	1.8	124
56	Better end points needed in primary sclerosing cholangitis trials. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 143-144.	8.2	5

#	Article	IF	Citations
57	NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter. Journal of Hepatology, 2019, 70, 348-350.	1.8	5
58	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 179-187.e6.	2.4	57
59	Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. Hepatology, 2020, 71, 214-224.	3.6	90
60	Drug Therapies for Chronic Cholestatic Liver Diseases. Annual Review of Pharmacology and Toxicology, 2020, 60, 503-527.	4.2	44
61	Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1576-1583.e1.	2.4	30
62	Primary sclerosing cholangitis: diagnostic performance of MRI compared to blood tests and clinical scoring systems for the evaluation of histopathological severity of disease. Abdominal Radiology, 2020, 45, 354-364.	1.0	3
63	Machine Learning in a Complex Disease: PREsTo Improves the Prognostication of Primary Sclerosing Cholangitis. Hepatology, 2020, 71, 8-10.	3.6	3
64	Recurrence of disease following organ transplantation in autoimmune liver disease and systemic lupus erythematosus. Cellular Immunology, 2020, 347, 104021.	1.4	9
65	Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2020, 55, 941-950.	0.6	31
66	Serum Matrix Metalloproteinase 7 Is a Diagnostic Biomarker of Biliary Injury and Fibrosis in Pediatric Autoimmune Liver Disease. Hepatology Communications, 2020, 4, 1680-1693.	2.0	14
67	Effective medical treatments for PSC needed ASAP - is AESOP the answer?. Journal of Hepatology, 2020, 73, 12-14.	1.8	1
68	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, 94-101.	1.8	111
69	Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. European Radiology, 2020, 30, 3735-3747.	2.3	17
71	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2295-2304.e2.	2.4	18
72	The MBOAT7 rs641738 variant is associated with an improved outcome in primary sclerosing cholangitis. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 646-652.	0.7	10
73	An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. Journal of Gastroenterology, 2020, 55, 523-532.	2.3	22
74	Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Digestive Diseases and Sciences, 2020, 65, 897-905.	1.1	21
75	Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. Journal of Gastroenterology, 2020, 55, 588-614.	2.3	49

#	Article	IF	Citations
76	What Clues Can We Use From Primary Sclerosing Cholangitis With Inflammatory Bowel Disease Phenotypes?. Clinical Gastroenterology and Hepatology, 2020, 18, 2173-2175.	2.4	0
77	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1248-1257.	2.4	25
78	Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease. JHEP Reports, 2021, 3, 100178.	2.6	7
79	Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs, 2021, 81, 333-347.	4.9	22
80	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 2021, 12, e00315.	1.3	10
81	Primary sclerosing cholangitis. Translational Gastroenterology and Hepatology, 2021, 6, 29-29.	1.5	24
82	Evaluation of circulating cell-free DNA in cholestatic liver disease using liver-specific methylation markers. BMC Gastroenterology, 2021, 21, 149.	0.8	3
83	The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities. Journal of Clinical Medicine, 2021, 10, 1763.	1.0	17
84	Treatment of primary sclerosing cholangitis. Digestive and Liver Disease, 2021, 53, 1531-1538.	0.4	16
85	Chronic cholestasis detection by a novel tool: automated analysis of cytokeratin 7-stained liver specimens. Diagnostic Pathology, 2021, 16, 41.	0.9	9
86	Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis. JHEP Reports, 2021, 3, 100286.	2.6	19
87	Collagen proportionate area correlates with histological stage and predicts clinical events in primary sclerosing cholangitis. Liver International, 2021, 41, 2681-2692.	1.9	7
88	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. Gastroenterology, 2021, 161, 1764-1775.e5.	0.6	28
89	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis â€“ 2021 update. Journal of Hepatology, 2021, 75, 659-689.	1.8	676
90	Systematic Review of Prognostic Models Compared to the Mayo Risk Score for Primary Sclerosing Cholangitis. Journal of Clinical Medicine, 2021, 10, 4476.	1.0	2
91	Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF. JHEP Reports, 2021, 3, 100328.	2.6	8
92	Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. Hepatology Communications, 2021, 5, 478-490.	2.0	20
93	Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. PLoS ONE, 2016, 11, e0164224.	1.1	45

#	Article	IF	Citations
94	Treatment of primary sclerosing cholangitis in children. World Journal of Hepatology, 2019, 11, 19-36.	0.8	28
95	Future Therapies for Primary Sclerosing Cholangitis. , 2017, , 153-166.		0
97	Primary Sclerosing Cholangitis Overlapping with IBD. , 2019, , 191-204.		0
98	Review of primary sclerosing cholangitis with increased IgG4 levels. World Journal of Gastroenterology, 2020, 26, 3126-3144.	1.4	26
99	PSC-AIH Overlap. , 2020, , 359-373.		0
101	Novel Bile Acid Therapies for Liver Disease. Gastroenterology and Hepatology, 2018, 14, 117-119.	0.2	2
102	Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment. Gastroenterology and Hepatology, 2018, 14, 293-304.	0.2	9
103	Emerging drugs for the treatment of primary sclerosing cholangitis. Current Opinion in Pharmacology, 2022, 62, 23-35.	1.7	5
104	Advances in genetic, epigenetic and environmental aspects of rare liver diseases. European Journal of Medical Genetics, 2022, 65, 104411.	0.7	1
105	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. Journal of Hepatology, 2022, 76, 841-849.	1.8	64
106	Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis. , 2022, 1, 287-295.		1
107	A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis. Hepatology Communications, 2022, 6, 1589-1597.	2.0	7
108	Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial. Efficacy and Mechanism Evaluation, 2022, 9, 1-54.	0.9	2
109	Novel histological scoring for predicting disease outcome in primary sclerosing cholangitis. Histopathology, 2022, , .	1.6	7
110	Promises of microbiome-based therapies. Journal of Hepatology, 2022, 76, 1379-1391.	1.8	33
111	EASL Clinical Practice Guidelines on sclerosing cholangitis. Journal of Hepatology, 2022, 77, 761-806.	1.8	84
112	Fenofibrate in primary sclerosing cholangitis; a randomized, doubleâ€blind, placeboâ€controlled trial. Pharmacology Research and Perspectives, 2022, 10, .	1.1	3
113	Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC. Clinical Gastroenterology and Hepatology, 2023, 21, 1552-1560.e2.	2.4	9

#	Article	IF	Citations
114	A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2022, 117, 1805-1815.	0.2	3
115	Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseasesâ€. Journal of Hepatology, 2023, 78, 430-441.	1.8	10
116	Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2023, 57, 23-36.	1.9	2
117	The microbiota and the gutâ€“liver axis in primary sclerosing cholangitis. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 135-154.	8.2	22
118	Algebraic topology-based machine learning using MRI predicts outcomes in primary sclerosing cholangitis. European Radiology Experimental, 2022, 6, .	1.7	5
119	Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study. Clinical Gastroenterology and Hepatology, 2023, 21, 3448-3450.e3.	2.4	4
120	Prognostic modeling in biliary diseases. Current Opinion in Gastroenterology, 2023, 39, 89-94.	1.0	0
121	Health-related quality of life and symptoms in autoimmune liver diseases. Minerva Gastroenterology, 2023, 69, .	0.3	0
122	PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis. BMC Gastroenterology, 2023, 23, .	0.8	4
123	Recent Advances in the Management of Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2023, 21, 2065-2075.	2.4	4
124	Artificial Intelligence Applications in Hepatology. Clinical Gastroenterology and Hepatology, 2023, 21, 2015-2025.	2.4	4